Methicillin resistant Staphylococcus aureus (MRSA) is a representative pathogen that is responsible for a nosocomial infection and considerable yearly mortality rate. Antibiotic resistance provides a great reason for immunotherapy as an alternative strategy to prevent and/or treat the infection.Herein, following the preparation of recombinant penicillin binding protein 2a (r-PBP2a), rabbit polyclonal IgG was purified. Specificity of IgG to r-PBP2a was evaluated by ELISA and western blotting. IgG fraction was prepared by sulfate ammonium precipitation. In addition opsonophagocytosis assay confirmed bioactivity of purified IgG. Experimental mice were challenged with lethal dose of MRSA (5 × 108) and mortality rate was recorded in the mice treated with IgG fraction for anti-rPBP2a, normal rabbit IgG, vancomycin therapy, and PBS control group. Bacterial quantity was evaluated by culture of liver, kidney and spleen homogenates. Results showed that passive immunization with anti r-PBP2a resulting in a significant improvement in survival rate as well as vancomycin treatment compared with control groups. Furthermore, anti r-PBP2a IgG enhanced considerably the phagocytosis of the S. aureus COL strain, reduced bacterial load, and inhibited the systemic spread of COL strain to the internal organs. These results confirmed that passive immunization by anti-r-PBP2a plays a considerable role in the control of infections caused by S. aureus similar to that of antibiotic therapy.
International Immunopharmacology – Elsevier
Published: Mar 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera